



Financial Results for the First Quarter of Fiscal Year Ending March 31, 2026

August 8, 2025

Stock Exchange Listings : Tokyo Stock Exchange

Company name : JMS Co., Ltd. (URL <https://www.jms.cc/english/>)
 Securities code : 7702
 Representative : Ryuji Katsura, President and Representative Director
 Inquiries : Yoshiki Ochiai , Executive Officer, Head of Corporate Affairs Division
 TEL : +81-82-243-5844
 Supplemental material of quarterly results : Yes Dividend payable date : —
 Convening briefing of quarterly results : None

(Note: Amounts below are rounded down to the nearest million yen)

1. Consolidated Financial Highlights for the Interim Period Ended June 2025 (From April 1, 2025 to June 30, 2025)

(1) Consolidated operating results

(%: change from the same previous period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended June 30, 2025	15,546	(3.9)	(176)	—	(283)	—	(459)	—
Three months ended June 30, 2024	16,177	10.8	42	—	194	—	(92)	—

(Note) Comprehensive income : Three months ended June 30, 2025 : (731) million yen [—%] ,
 Three months ended June 30, 2024 : 1,200 million yen [4.1%] .

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Three months ended June 30, 2025	(18.76)	—
Three months ended June 30, 2024	(3.77)	—

(2) Consolidated financial positions

	Total assets	Net assets	Capital adequacy ratio
	Millions of yen	Millions of yen	%
As at June 30, 2025	80,332	39,986	49.7
As at March 31, 2025	81,432	40,927	50.1

(Note) Owner's equity: June 30, 2025: 39,905 million yen, March 31, 2025: 40,835 million yen.

2. Dividends

	Dividend per share				
	1st quarter	2nd quarter	3rd quarter	Fiscal Year end	Annual
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2025	—	8.50	—	8.50	17.00
Year ending March 31, 2026	—				
Year ending March 31, 2026 (forecast)		8.50	—	8.50	17.00

(Note) Correction of dividend forecast from the most recent dividend forecast: None

3. Consolidated Forecast for the Year Ending March 2026 (From April 1, 2025 to March 31, 2026)

(%: change from the same previous period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Half year ending September 30, 2025	33,800	(0.1)	350	125.3	300	—	100	—	4.08
Year ending March 31, 2026	68,000	(2.5)	900	3.1	600	16.5	200	123.4	8.16

(Note) Correction of financial forecast from the most recent financial forecast. : None

The aforementioned projections are based on the information currently available, and may contain some uncertainties.
 The final results might be significantly different from the aforementioned projections due to changes in business conditions.

4. Overview of business result for the first quarter

(1) Overview of consolidated business results

JMS strives to improve the quality of corporate management and the corporate value, in order 'To be a bridge for the people who give and seek medical care, and to bring a smile to people by contributing to a healthy and better life' under our Founding Spirit of 'For People's Precious Life'. JMS focused on four fields of business activities such as Infusion & Enteral Nutrition, Dialysis, Cardiovascular and Blood Management & Cell Therapy and promotes product development, production and sales.

During the consolidated cumulative first quarter, sales of medical gloves declined in Japan, but sales of Closed Drug Mixing/Infusion Systems, which are being promoted as a priority business, and Dysphagia-related products, for which demand is expanding, continued to grow. In overseas markets, sales of AV Fistula Needles remained strong, while sales of Apheresis Kits for North America and sales related to the hemodialysis business in China declined.

As a result, Net sales decreased by 630 million yen from the same quarter of the previous fiscal year to 15,546 million yen (down 3.9% year-over-year). Despite the reduction in manufacturing expenses, Operating loss was 176 million yen (Operating profit of 42 million yen in the same period of the previous year) due to a decrease in sales of overseas main products and an increase in selling expenses. Although there was an investment gain under the equity method, foreign exchange losses were recorded due to unfavorable exchange rate movements, resulting in an Ordinary loss of 283 million yen (Ordinary profit of 194 million yen in the same period of the previous year). After deducting income taxes, net loss attributable to owners of the parent was 459 million yen (compared to a net loss of 92 million yen in the same period of the previous year).

Business performance by geographical segment.

(i) Japan

Net sales decreased 1.5% year-over-year to 10,545 million yen, due to continued growth in sales of Closed Drug Mixing/Infusion Systems and Dysphagia-related products, but sales of Hemodialysis Business in China and Acute Blood Purification products remained sluggish. Segment profit was 121 million yen (down 52.0% year-over-year) due to an increase in selling, general and administrative expenses from operating activities, in addition to increases in labor and electricity costs.

(ii) Singapore

Net sales decreased 1.7% year-over-year to 5,639 million yen, due to a decline in sales of Apheresis Kits for North America. Segment loss was 248 million yen (compared to a profit of 40 million yen in the same period of the previous year) due to a decrease in sales of major products and the unfavorable impact of foreign exchange rates, which resulted in foreign exchange losses.

(iii) China

Net sales decreased 8.7% year-over-year to 922 million yen, due to sluggish sales of Hemodialysis Machines and AV Fistula Needles. Segment profit was 1 million yen (compared to a loss of 36 million yen in the same period of the previous year) due to favorable exchange rates, despite higher raw material costs and labor costs.

(iv) Philippines

Net sales decreased 7.8% year-over-year to 839 million yen, due to a decrease in sales of Blood Bags and Apheresis Kits in Asia, despite an increase in sales of Infusion Sets in Japan. Segment loss was 150 million yen (compared to a loss of 149 million yen in the same period of the previous year), due to a decrease in operating rates accompanying a decline in sales of Blood Bags, as well as an increase in labor costs and other expenses.

(v) Germany

Net sales increased 15.1% year-over-year to 1,080 million yen, due to strong sales of AV Fistula Needles and Blood Bags for the European market. Segment profit increased 73.9% year-over-year to 129 million yen due to the increase in sales.

(vi) Others

Net sales increased 28.8% year-over-year to 1,483 million yen, mainly due to strong sales of AV Fistula Needles

for North America. Segment loss was 43 million yen (compared to a loss of 12 million yen in the same period of the previous year).

(2) Overview of the financial condition

Total assets at the end of the first quarter of the current consolidated fiscal year decreased by 1.1 billion yen from the end of the previous consolidated fiscal year to 80,332 million yen. The details of assets, liabilities, and net assets are as follows.

(Assets)

Current assets decreased by 163 million yen from the end of the previous fiscal year to 45,609 million yen. The main reason for this decrease was a decrease in notes and accounts receivable. Fixed assets decreased by 936 million yen from the end of the previous fiscal year to 34,722 million yen. The main reason for this decrease was a decrease in tangible fixed assets.

(Liabilities)

Current liabilities increased by 122 million yen from the end of the previous fiscal year to 25,751 million yen. This was mainly due to an increase in short-term loans payable. Non-current liabilities decreased by 281 million yen from the end of the previous fiscal year to 14,594 million yen. This was mainly due to a decrease in long-term loans payable.

(Net assets)

Net assets decreased by 940 million yen from the end of the previous fiscal year to 39,986 million yen. This decrease was primarily due to fluctuations in foreign currency translation adjustments. In addition, the equity ratio decreased by 0.4 percentage points from the end of the previous fiscal year to 49.7%.

(3) Overview of consolidated business forecast

Amid continuing uncertainty in the economic and business environment, we will continue to closely monitor the impact of various risks on JMS's business results. At this point, there are no changes to the consolidated earnings forecasts for the first half and full year announced on May 9, 2025.

5. Consolidated Financial Statements

Consolidated Balance Sheet

JMS CO., LTD. and Consolidated Subsidiaries

(Millions of yen)

	<u>As at March 31,</u> <u>2025</u>	<u>As at June 30,</u> <u>2025</u>
Assets		
Current assets		
Cash and deposits	5,511	6,196
Notes and accounts receivable - trade	18,636	17,052
Merchandise and finished goods	10,913	11,204
Work in process	3,667	3,890
Raw materials and supplies	6,106	6,348
Other	945	923
Allowance for doubtful accounts	(7)	(5)
Total current assets	<u>45,773</u>	<u>45,609</u>
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	9,841	9,617
Machinery, equipment and vehicles, net	8,821	8,938
Other, net	9,627	8,927
Total property, plant and equipment	<u>28,291</u>	<u>27,483</u>
Intangible assets		
Goodwill	296	276
Other	647	627
Total intangible assets	<u>943</u>	<u>904</u>
Investments and other assets		
Investments and other assets	6,498	6,413
Allowance for doubtful accounts	(75)	(78)
Total investments and other assets	<u>6,423</u>	<u>6,334</u>
Total non-current assets	<u>35,658</u>	<u>34,722</u>
Total assets	<u>81,432</u>	<u>80,332</u>

Consolidated Balance Sheet

JMS CO., LTD. and Consolidated Subsidiaries

(Millions of yen)

	<u>As at March 31,</u> <u>2025</u>	<u>As at June 30,</u> <u>2025</u>
Liabilities		
Current liabilities		
Notes and accounts payable - trade	7,951	7,231
Short-term borrowings	5,072	5,813
Current portion of long-term borrowings	6,002	5,897
Income taxes payable	357	88
Provision for bonuses	1,040	635
Other	5,203	6,084
Total current liabilities	<u>25,629</u>	<u>25,751</u>
Non-current liabilities		
Long-term borrowings	11,793	11,645
Provision for retirement benefits for directors (and other officers)	171	168
Retirement benefit liability	574	586
Asset retirement obligations	329	335
Other	2,006	1,858
Total non-current liabilities	<u>14,875</u>	<u>14,594</u>
Total liabilities	<u>40,504</u>	<u>40,345</u>
Net assets		
Shareholders' equity		
Share capital	7,411	7,411
Capital surplus	10,351	10,351
Retained earnings	16,723	16,055
Treasury shares	(177)	(177)
Total shareholders' equity	<u>34,308</u>	<u>33,640</u>
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	1,073	1,059
Foreign currency translation adjustment	5,453	5,205
Total accumulated other comprehensive income	<u>6,526</u>	<u>6,264</u>
Non-controlling interests	91	81
Total net assets	<u>40,927</u>	<u>39,986</u>
Total liabilities and net assets	<u>81,432</u>	<u>80,332</u>

Consolidated statements of income

JMS CO., LTD. and Consolidated Subsidiaries

(Millions of yen)

	<u>Three months ended</u> <u>June 30, 2024</u>	<u>Three months ended</u> <u>June 30, 2025</u>
Net sales	16,177	15,546
Cost of sales	12,541	11,995
Gross profit	3,635	3,551
Selling, general and administrative expenses	3,592	3,727
Operating profit (loss)	42	(176)
Non-operating income		
Interest income	3	2
Dividend income	31	46
Share of profit of entities accounted for using equity method	102	55
Foreign exchange gains	79	—
Other	25	21
Total non-operating income	242	125
Non-operating expenses		
Interest expenses	79	84
Foreign exchange losses	—	144
Other	12	4
Total non-operating expenses	91	233
Ordinary profit (loss)	194	(283)
Extraordinary income		
Gain on sale of non-current assets	0	2
Gain on sale of investment securities	—	0
Total extraordinary income	0	2
Extraordinary losses		
Loss on abandonment of non-current assets	5	1
Total extraordinary losses	5	1
Profit (loss) before income taxes	189	(282)
Income taxes - current	28	81
Income taxes - deferred	248	104
Total income taxes	277	185
Loss	(87)	(468)
Profit (loss) attributable to non-controlling interests	4	(9)
Loss attributable to owners of parent	(92)	(459)

Consolidated statements of comprehensive income

JMS CO., LTD. and Consolidated Subsidiaries

(Millions of yen)

	<u>Three months ended</u> <u>June 30, 2024</u>	<u>Three months ended</u> <u>June 30, 2025</u>
Loss	(87)	(468)
Other comprehensive income		
Valuation difference on available-for-sale securities	91	(14)
Foreign currency translation adjustment	1,196	(248)
Total other comprehensive income	<u>1,288</u>	<u>(262)</u>
Comprehensive income	<u>1,200</u>	<u>(731)</u>
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	1,191	(721)
Comprehensive income attributable to non-controlling interests	9	(10)